BioTek reMEDys to provide Uplizna

BioTek reMEDys, one of the nation’s largest specialty infusion pharmacies focused on rare diseases, has added Uplizna to its specialty therapeutics portfolio to provide treatment to a broader patient population and further expand upon its diverse pharmaceutical product offering.

Uplizna is used to treat adults with neuromyelitis optica spectrum disorder who are anti-aquaporin-4 antibody positive.

[Read more: Retailers bolster specialty pharmacy capabilities as its role in industry grows]

NMOSD, also known as Devic disease, is a chronic disorder of the brain and spinal cord dominated by inflammation of the optic nerve (optic neuritis) and inflammation of the spinal cord (myelitis). For these patients, Uplizna is proven to help reduce relapses that could lead to permanent disabilities.

“The clinical evidence surrounding Uplizna in the treatment of NMOSD patients has been overwhelmingly positive,” said Carla Sparkler, BioTekreMEDys’ chief marketing officer. “We are proud to have access to this limited distribution drug and to care for this patient population.”

[Read more: Retailers build out their specialty pharmacy offerings]

Effective immediately, Uplinza will be available at all BioTek reMEDys locations.